Forte Biosciences, Inc. (FBRX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody for autoimmune indications. Key clinical milestones include the initiation of a Phase 2 study for celiac disease in July 2025 following positive Phase 1b data announced in June 2025. The company is also advancing Phase 1b trials for non-segmental vitiligo and alopecia areata.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(17.7) million | $(8.4) million | $(44.6) million | $(28.3) million |
| Net Loss Per Share (Basic/Diluted) | $(0.99) | $(4.54) | $(3.26) | $(15.35) |
| Operating Expenses | $18.4 million | $8.6 million | $46.1 million | $29.3 million |
| Cash and Cash Equivalents (Sept 30, 2025) | $93.4 million | |||
| Accumulated Deficit (Sept 30, 2025) | $(198.6) million | |||
| Net Cash Used in Operating Activities (YTD) | $(34.4) million | $(20.7) million |
Material Changes vs. Prior Period
- Significant Capital Raise: In June 2025, the Company closed a public offering raising gross proceeds of $75.0 million. In July 2025, underwriters exercised an option for an additional $1.8 million. This significantly increased cash balances from $22.2 million at year-end 2024 to $93.4 million at September 30, 2025.
- Increased R&D Spend: Research and development expenses increased to $15.2 million for Q3 2025 (from $5.9 million in Q3 2024) and $36.5 million YTD 2025 (from $16.0 million YTD 2024). This increase is primarily due to clinical and manufacturing costs for the Phase 2 celiac trial and Phase 1b trials for vitiligo and alopecia areata.
- Share Count Expansion: Outstanding common shares increased from 6.4 million (Dec 31, 2024) to 12.5 million (Sept 30, 2025) due to the public offering and warrant exercises.
- Legal Settlements: General and administrative expenses decreased YTD 2025 compared to 2024, largely due to a $6.0 million reduction in legal and settlement expenses related to prior litigation (Camac Fund).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash of $93.4 million is sufficient to fund operations for at least 12 months from the filing date. The company expects to continue incurring losses as it advances FB102.
- Clinical Timeline: Topline data for the Phase 2 celiac study is expected in 2026. Topline data for vitiligo and alopecia areata Phase 1b trials are also expected in 2026.
- Key Risks:
- Capital Requirements: The company has no approved products and no revenue. It will require additional capital to complete development and commercialization. Failure to secure funding could force delays or termination of programs.
- Development Risk: FB102 is the sole product candidate. Positive Phase 1b results do not guarantee Phase 2 success or regulatory approval.
- Legal Proceedings: The company is involved in litigation regarding insurance coverage for prior director/officer claims (Wesco Complaint) and has settled prior shareholder disputes.
Investor Verification Checklist
- Verify the specific burn rate and cash runway beyond the stated 12-month period given the acceleration of Phase 2 clinical costs.
- Review the terms of the June 2025 public offering and the status of outstanding pre-funded warrants (5.3 million shares) for potential dilution.
- Monitor the status of the Forte Biosciences, Inc. v. Wesco Insurance Co. litigation regarding D&O insurance coverage.
- Confirm the enrollment progress and data readout dates for the Phase 2 celiac study and Phase 1b vitiligo/alopecia areata trials.
- Assess the impact of the 1-for-25 reverse stock split (effective August 2024) on historical share counts and per-share metrics.